2017 American Transplant Congress
Tacrolimus and Mycophenolate Exposure and Subclinical Tubulo-Interstitial Inflammation in Low Immunological Risk Renal Transplants.
The aim is to evaluate the relationship between maintenance immunosuppression, subclinical inflammation (i-score plus t-score) and interstitial fibrosis/tubular atrophy (IF/TA) (ci-score plus ct-score) in paired…2017 American Transplant Congress
Mycophenolic Acid Needs Ca2+ to Exert Its Anti-inflammatory Action via Shedding of Toll-Like Receptor4 and Tumor Necrosis Factor Receptor 1.
Background Mycophenolic acid (MPA) has been used for many years to prevent transplantation rejection. Recently, it has been investigated for its anti-inflammatory effects. MPA can…2017 American Transplant Congress
Immunosuppressive Regimen Modification Approaches in BK Nephropathy – A Comparative Study.
Department of Medicine, University of Maryland Medical Center, Baltimore, MD
The optimal approach for IS reduction in renal transplant recipients with BKN is not well defined. A number of clinical and in vitro studies suggest…2017 American Transplant Congress
Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race.
Transplant, MUSC, Charleston, SC
There is strong evidence that both tacrolimus (FK) and mycophenolate (MMF) have improved outcomes in kidney transplantation; yet, the impact of exposure of these immunosuppressants…2017 American Transplant Congress
Impact of Intensive Dosing of Mycophenolate on Pancreas Allograft Survival.
1Pharmacy, UW Health, Madison, WI; 2Transplant Surgery, UW Health, Madison, WI
Purpose: The primary objective was to evaluate the effect of mycophenolate (MPA) dicharge (DC) dose on pancreas allograft (PTX) survival. Secondary endpoints included patient survival…2017 American Transplant Congress
Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome.
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well determined. We have validated the institutional…2016 American Transplant Congress
Benefit of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation with 2 Years Follow-Up.
Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression in order to further reduction of EVR and CNI was evaluated in clinical…2016 American Transplant Congress
Achieving Timely Therapeutic Mycophenolic Acid Levels in Pediatric Lung Transplant Patients.
Texas Children's Hospital, Houston, TX.
The purpose of this study was to determine the appropriate initial dose of mycophenolate mofetil (MMF) in pediatric cystic fibrosis (CF) and non-CF lung transplant…2016 American Transplant Congress
Mycophenolate Mofetil Single Dose Pharmacokinetics Following Laparoscopic Sleeve Gastrectomy.
The influence of various metabolic surgery procedures on immunosuppressant pharmacokinetics (PK) is largely unknown. For laparoscopic sleeve gastrectomy (LSG) (currently the most common procedure) no…2016 American Transplant Congress
Marked Alterations in Gene Expression in Peripheral Blood Leukocytes of Kidney Transplant (tx) Recipients Following Mycophenolic Acid (MPA) Treatment.
1University of Minnestoa, Minneapolis; 2MMRC, Hennepin County Medical Center, Minneapolis; 3Rho.
MPA exerts its immunosuppressive activity by inhibiting IMPDH2 enzyme, halting DNA synthesis in T and B lymphocytes. Cell culture models have shown MPA effects on…
American Transplant Congress abstracts